Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedMay 30, 2026
DataAggregated Company Financials
Companies20
  • 7D1.1%
  • 3M15.5%
  • 1Y-30.1%
  • YTD-11.5%

In the last week, the Healthcare industry is up 1.1%, with Novo Nordisk up 1.4%. In the past year, the industry is down 30%. Earnings are forecast to grow by 2.9% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 30 May 2026DKK 1.7tDKK 468.5bDKK 147.0b20.7x11.8x3.7x
Mon, 27 Apr 2026DKK 1.6tDKK 447.3bDKK 129.9b18.3x12x3.5x
Wed, 25 Mar 2026DKK 1.4tDKK 447.6bDKK 130.0b16.3x11.1x3.2x
Fri, 20 Feb 2026DKK 1.8tDKK 447.5bDKK 131.0b18x13.8x4x
Sun, 18 Jan 2026DKK 2.2tDKK 454.1bDKK 137.0b18.6x16.4x4.9x
Tue, 16 Dec 2025DKK 1.9tDKK 453.7bDKK 136.9b16.9x13.9x4.2x
Thu, 13 Nov 2025DKK 1.9tDKK 453.4bDKK 136.0b18.2x14.2x4.3x
Sat, 11 Oct 2025DKK 2.2tDKK 447.6bDKK 141.8b18.2x15.4x4.9x
Mon, 08 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.5x4.6x
Wed, 06 Aug 2025DKK 1.8tDKK 423.5bDKK 124.6b29.5x14.5x4.3x
Fri, 04 Jul 2025DKK 2.4tDKK 423.0bDKK 124.4b30.5x19.2x5.6x
Sun, 01 Jun 2025DKK 2.5tDKK 423.9bDKK 124.7b30.4x19.9x5.8x
Tue, 29 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b22x19x5.6x
Thu, 27 Mar 2025DKK 2.7tDKK 409.6bDKK 121.3b23.5x22.3x6.6x
Sat, 22 Feb 2025DKK 3.3tDKK 410.0bDKK 121.4b28.1x27.6x8.2x
Mon, 20 Jan 2025DKK 3.1tDKK 387.5bDKK 111.3b28.5x27.9x8x
Wed, 18 Dec 2024DKK 3.9tDKK 387.4bDKK 111.3b30.1x35.5x10.2x
Fri, 15 Nov 2024DKK 3.9tDKK 387.1bDKK 110.8b31.9x35.3x10.1x
Sun, 13 Oct 2024DKK 4.2tDKK 372.0bDKK 107.1b37x39.3x11.3x
Tue, 10 Sep 2024DKK 4.5tDKK 372.0bDKK 107.2b35x42.5x12.2x
Thu, 08 Aug 2024DKK 4.3tDKK 355.3bDKK 106.3b36.2x40.2x12x
Sat, 06 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.3x46.2x13.8x
Mon, 03 Jun 2024DKK 4.7tDKK 355.3bDKK 106.2b36.8x44.1x13.2x
Wed, 01 May 2024DKK 4.6tDKK 341.4bDKK 99.6b33.7x46x13.4x
Fri, 29 Mar 2024DKK 4.5tDKK 341.2bDKK 99.6b39.2x45.4x13.3x
Sun, 25 Feb 2024DKK 4.4tDKK 340.1bDKK 98.9b38.2x44.2x12.9x
Tue, 23 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b35.2x41.8x11.7x
Thu, 21 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b32.6x40.1x11.3x
Sat, 18 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b33.7x40x11.2x
Mon, 16 Oct 2023DKK 3.7tDKK 305.5bDKK 82.2b30.7x45x12.1x
Wed, 13 Sep 2023DKK 3.2tDKK 305.5bDKK 82.2b35.3x39x10.5x
Fri, 11 Aug 2023DKK 3.3tDKK 288.2bDKK 74.9b42.1x44.4x11.5x
Sun, 09 Jul 2023DKK 2.9tDKK 287.0bDKK 75.5b39.4x38.9x10.2x
Tue, 06 Jun 2023DKK 3.0tDKK 287.2bDKK 75.5b39.7x39.6x10.4x
Price to Earnings Ratio

39.6x


Total Market Cap: DKK 3.0tTotal Earnings: DKK 75.5bTotal Revenue: DKK 287.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 30.1x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.8x which is lower than its 3-year average PE of 30.1x.
  • The 3-year average PS ratio of 8.7x is higher than the industry's current PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market0.43%
Healthcare1.09%
Life Sciences8.41%
Pharma1.46%
Healthtech-0.078%
Medical Equipment-0.62%
Biotech-0.97%
Healthcare Services-6.57%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 33.2x.
    • Analysts are expecting annual earnings growth of 20.2%, which is higher than its past year's earnings growth of 0.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 11% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 292.951.4%
+DKK 17.5b		-35.4%PE10.6x
HLUN B H. LundbeckDKK 43.423.8%
+DKK 1.6b		19.5%PE11.5x
ALK B ALK-AbellóDKK 268.001.9%
+DKK 1.1b		50.6%PE46.4x
CHEMM ChemoMetecDKK 375.0011.5%
+DKK 675.2m		-29.0%PE36.9x
DEMANT DemantDKK 250.201.2%
+DKK 632.7m		-2.6%PE22.3x

Latest News

ZEAL
DKK 324.90
Zealand Pharma
7D
2.2%
1Y
-28.4%
ALK B
DKK 268.00
ALK-Abelló
7D
1.9%
1Y
50.6%
Narrative Update • May 29

ALK B: Future Upside Will Come From Allergy Immunotherapy Leadership

Analysts have lifted their price target on ALK-Abelló from DKK 263.33 to DKK 297.50, citing the company’s position as a global leader in allergy immunotherapy and recent supportive research coverage. Analyst Commentary Analysts setting a DKK 305 price target frame ALK-Abelló as a global leader in allergy immunotherapy, and they use that positioning to support a constructive view on the stock’s long term potential.
NOVO B
DKK 292.95
Novo Nordisk
7D
1.4%
1Y
-35.4%
HLUN B
DKK 43.42
H. Lundbeck
7D
3.8%
1Y
19.5%
GUBRA
DKK 357.40
Gubra
7D
5.1%
1Y
-8.3%
Narrative Update • May 26

GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside

Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.
GMAB
DKK 1,704.00
Genmab
7D
-1.1%
1Y
23.5%
Narrative Update • May 26

GMAB: Late Stage Oncology Readouts Will Support Stronger Margins And Earnings Quality

Genmab's analyst price target has been trimmed slightly to DKK 3,000, as analysts factor in more measured revenue growth expectations, a modestly higher discount rate, and a somewhat richer forward P/E outlook. They are still pointing to solid margin potential and recent bullish rating updates from several firms.
DEMANT
DKK 250.20
Demant
7D
1.2%
1Y
-2.6%
SMSMED
DKK 2.70
Scandinavian Medical Solutions
7D
-6.6%
1Y
-45.2%
BAVA
DKK 187.40
Bavarian Nordic
7D
-4.9%
1Y
8.3%
COLO B
DKK 395.80
Coloplast
7D
-1.9%
1Y
-37.7%
Analysis Article • May 20

Some May Be Optimistic About Coloplast's (CPH:COLO B) Earnings

Shareholders appeared unconcerned with Coloplast A/S' ( CPH:COLO B ) lackluster earnings report last week. Our analysis...
EMBLA
DKK 27.55
Embla Medical hf
7D
2.2%
1Y
-15.7%
Narrative Update • May 19

EMBLA: Share Cancellations And Renewed Capital Authorisations Will Support Future Upside

Analysts have kept their DKK price target for Embla Medical hf. broadly steady at DKK 33.3, reflecting only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions in their updated models.
AMBU B
DKK 67.40
Ambu
7D
-1.1%
1Y
-33.5%
Narrative Update • May 19

AMBU B: Lower P/E Expectations Will Support Future Upside Repricing

Analysts have trimmed their price target on Ambu from DKK 110.34 to DKK 88.80, reflecting a more cautious stance following a downgrade in recent research. The revised target still assumes steady revenue growth and a lower future P/E multiple.
CHEMM
DKK 375.00
ChemoMetec
7D
11.5%
1Y
-29.0%
STENO
DKK 1.12
Stenocare
7D
-2.6%
1Y
168.7%
VIRO
DKK 10.70
ViroGates
7D
-1.8%
1Y
31.8%
PEG
DKK 0.077
Pharma Equity Group
7D
-2.5%
1Y
-20.7%